Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Cabrini Health, Melbourne;Monash University, Melbourne
Prince of Wales Hospital, Randwick, Sydney
Westmead Hospital, Sydney
Icon Cancer Care, Brisbane
Concord Hospital University of Sydney;University of Sydney
Royal North Shore Hospital, St Leonards
Haematology Department, Royal Adelaide Hospital;School of Medicine, Univeristy of Adelaide;Cancer Theme, South Australian Health and Medical Research (SAHMRI), Adelaide
Border Medical Oncology, Albury
Austin Health, Melbourne
Andrew Love Cancer Centre, University Hospital, Geelong
Victorian Cancer Cytogenetics Service, St Vincent’s Hospital, Fitzroy, Victoria;Department of Medicine, St Vincent’s Hospital, University of Melbourne, Fitzroy, Victoria;St Vincent’s Institute of Medical Research, Fitzroy, Victoria
Peter MacCallum Cancer Centre, Melbourne;Sir Peter MacCallum Department of Oncology, University of Melbourne
Australasian Leukaemia and Lymphoma Group, Richmond
Australasian Leukaemia and Lymphoma Group, Richmond;Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne;Department of Medical Biology, University of Melbourne
Australasian Leukaemia and Lymphoma Group, Richmond
Peter MacCallum Cancer Centre, Melbourne;University of Melbourne, Australia
Vol. 104 No. 4 (2019): April, 2019